HSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
BUZZ-HSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's ** HSBC maintains "buy" and raises TP to 1,525 rupees from 1,375 rupees on Dr. Reddy's Laboratories REDY.NS, citing better pricing for semaglutide and stronger growth for India formulations
** Rates "buy" on Apollo Hospitals APLH.NS, Aster DM ATRD.NS, Torrent Pharmaceuticals TORP.NS and Glenmark Pharmaceuticals GLEN.NS, citing stronger earnings visibility** Brokerage notes that Q2FY27 healthcare earnings were largely in-line, driven by healthy trends in India formulation business and key launches in the U.S.
** Says outlook for health care looks intact despite concerns from trade margin cap on Oncology drugs
** Notes limited impact from higher input and logistics costs due to the Middle East situation; remains watchful
(Reporting by Anushka Rajvedi in Bengaluru)
((mailto: anushka.rajvedi@thomsonreuters.com))
Recent news on Torrent Pharmaceuticals
See all newsHSBC sees steady growth for India healthcare; raise TP on Dr. Reddy's
India's Torrent Pharma's profit slips as R&D costs outweigh domestic demand
Brief: Torrent Pharma Q2 Consol Net Profit 5.34 Billion Rupees
GLP-1 boom in China, India, Brazil could create $22 bln market by 2035, J.P. Morgan says
India's Torrent Pharma Q2 earnings to get an acquisition lift, Nomura says